Cholesterol, total; DRI; high-density lipoprotein (HDL) cholesterol; low-density lipoprotein (LDL) cholesterol (calculation); non-high-density lipoprotein (non-HDL) cholesterol (calculation = total cholesterol minus HDLC); triglycerides
1 - 3 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Serum, shipped refrigerated, or plasma
0.5 mL (Note: This volume does not allow for repeat testing.)
Plain red-top tube (preferred); NMR LipoTube (black-and- yellow-top tube), lavender-top (EDTA-no gel) tube, or green-top (heparin-no gel) tube is acceptable.
Collect specimen in plain red-top tube (no gel), which is the preferred specimen. Hold tube upright at room temperature for 45 minutes and allow to clot. Centrifuge specimen after clotting according to manufacturer's specifications. Transfer to a transport tube for storage at (2°C to 8°C) until shipped.
For NMR LipoTube (black-and-yellow-top tube), keep upright at room temperature for 30 minutes and allow to clot. Centrifuge at 1800 to 2200xg for 10 to 15 minutes immediately after clotting. If the sample cannot be centrifuged immediately, it must be refrigerated at (2°C to 8°C) and centrifuged within 24 hours of collection. The NMR tube should then be stored at (2°C to 8°C) until shipped.
Separate plasma from lavender-top (EDTA-no gel) tube or green-top (heparin-no gel) tube immediately after collection and transfer to a plastic transport tube for shipment to the laboratory.
Serum or plasma drawn in gel-barrier collection tubes other than the NMR LipoTube should not be used.
LipoTube Serum: 1 day; Plain Serum: 1 day; EDTA Plasma: 8 hours; Sodium Heparin Plasma: 8 hours
LipoTube Serum: 8 days; Plain Serum: 8 days; EDTA Plasma: 8 days; Sodium Heparin Plasma: 7 days
All tubes: 15 days (Note: Triglyceride values in frozen samples with high values >400 mg/dL may be decreased more than 10% when frozen.)
LipoTube Serum: Stable x5; Plain Serum: Stable x1; EDTA Plasma: Stable x5; Sodium Heparin Plasma: Stable x2
Patient fasting is not required; however, in conditions where triglyceride values provide a priori diagnostic information, such as screening for familial hypercholesterolemia or early onset heart disease, pancreatitis, or confirming hypertriglyceridemia, the patient should be counseled to fast 12 to 14 hours prior to blood draw.
Unspun LipoTube or unseparated plain red-top or EDTA tube; serum or plasma specimen drawn in gel-barrier collection tube other than the NMR LipoTube
The Diabetes Risk Index (DRI) is intended for use in adult subjects for the quantitative determination of a risk score in serum or plasma. The DRI score (1-100) may be used as an aid in stratifying the risk of developing type 2 diabetes in individuals with normo-glycemia or prediabetes. The Diabetes Risk Index (DRI) is a nuclear magnetic resonance spectroscopy (NMR)-derived multimarker score (values 1-100) that predicts a patient's risk of developing type 2 diabetes mellitus (T2D) independent of glycemic status. DRI derives its performance from the weighted addition of the Lipoprotein Insulin Resistance Index (LP-IR) scores with simultaneously-measured levels of branched-chain amino acids (BCAA).1-6
For clinical use, DRI can be divided into three groups, corresponding to a low, intermediate, and high risk of developing T2D, with cutpoints corresponding closely to the 40th and 80th percentile values in the Multi-Ethnic Study of Atherosclerosis (MESA) reference population, using gender-specific cutpoints. Therefore, the low DRI category would include men and women with DRI scores less than 50 and 40, respectively. The intermediate DRI category would include men with DRI 50-65 and women with DRI 40-55. The high DRI group would consist of men and women with DRI >65 and >55, respectively.
If triglyceride level is >800 mg/dL, LDL cholesterol will not be calculated.
DRI measurements from plasma specimens are on average 8 points lower than from serum specimens.
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
Nuclear magnetic resonance (NMR)
LP-IR is a marker of insulin resistance, and as such the LP-IR score predicts a patient's likelihood of future development of T2D.1-4 LP-IR is a multimarker index (values 0-100) based on the concentrations of particular lipoprotein subclasses [very large and large triglyceride-rich lipoprotein particles (VLL-TRLP), small low density lipoprotein particles (S-LDLP), large high density lipoprotein particles (L-HDLP), and mean TRL, LDL, and HDL particle sizes (TRLZ, LDLZ, HDLZ)]. The medical decision limits established for LPIR are <50 (low), 50-80 (intermediate), and >80 (high) with these cutpoints corresponding to the 25th and 75th percentiles in a normal population. DRI builds on the effective insulin resistance assessment by LP-IR and adds the measurement of BCAA. Similar to LP-IR, BCAA have also been shown to predict incident T2DM.5,6 The analytes contributing to DRI are measured by mathematical deconvolution of the methyl signal region of the plasma/serum NMR spectrum. This algorithm is different from the NMR LipoProfile test in that the methyl region is extended downfield to include signals from the BCAA (valine and leucine).
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|123525||Lipid Panel+DRI||123477||Cholesterol, Total||mg/dL||2093-3|
|123525||Lipid Panel+DRI||123478||Non-HDL Cholesterol||mg/dL||43396-1|
|123525||Lipid Panel+DRI||123479||LDL-C (NIH Calc)||mg/dL||13457-7|
|123525||Lipid Panel+DRI||123856||Diabetes Risk Index (DRI)||94560-0|
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf